Lee Ainslie Sqz Biotechnologies CO Transaction History

Maverick Capital LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.27 - $0.68 $400 - $1,009	-1,485 Reduced 0.14%	1,050,286 $283,000
Q1 2023 May 15, 2023	SELL	$0.53 - $0.87 $8,683 - $14,254	-16,384 Reduced 1.53%	1,051,771 $588,000
Q2 2022 Aug 15, 2022	BUY	$2.77 - $5.0 $31,492 - $56,845	11,369 Added 1.08%	1,068,155 $3.4 Million
Q3 2021 Nov 15, 2021	BUY	$11.46 - $15.77 $844,487 - $1.16 Million	73,690 Added 7.5%	1,056,786 $15.2 Million
Q2 2021 Aug 16, 2021	BUY	$11.32 - $14.45 $263,348 - $336,164	23,264 Added 2.42%	983,096 $14.2 Million
Q1 2021 May 17, 2021	BUY	$12.07 - $29.9 $288,002 - $713,443	23,861 Added 2.55%	959,832 $13.1 Million
Q4 2020 Feb 16, 2021	BUY	$13.25 - $34.58 $12.4 Million - $32.4 Million	935,971 New	935,971 $27.1 Million

1.47M

Ticker SQZ
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,248,600
Market Cap $1.46M
Description
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination ...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.